| 000 | 02616nam a22003737a 4500 | ||
|---|---|---|---|
| 008 | 210628s20212021 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a1774-024X | ||
| 024 | _a10.4244/EIJ-D-21-00012 [doi] | ||
| 024 | _aEIJ-D-21-00012 [pii] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a34031024 | ||
| 245 | _aIncidence and Standardized Definitions of Mitral Valve Leaflet Adverse Events After Transcatheter Mitral Valve Repair: the EXPAND Study. | ||
| 251 | _aEurointervention. 2021 May 25 | ||
| 252 | _aEuroIntervention. 2021 May 25 | ||
| 253 | _aEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology | ||
| 260 | _c2021 | ||
| 260 | _fFY2021 | ||
| 260 | _p2021 May 25 | ||
| 265 | _saheadofprint | ||
| 266 | _d2021-06-28 | ||
| 520 | _aAIMS: We aimed to report the findings of the expert panel and standardize definitions for LAE. | ||
| 520 | _aBACKGROUND: An independent panel of experts reviewed all investigator-reported cases of mitral valve leaflet adverse events (LAE) after MitraClipTM NTR/XTR in the EXPAND Study. | ||
| 520 | _aCONCLUSIONS: Mitral valve repair with MitraClipTM NTR/XTR is safe. The rate of LAE is lower than previously reported using older generation devices. The proposed definitions and findings will help differentiate leaflet injury from inadequate leaflet insertion and SLDA, and provide guidance to consistently diagnose LAE post MitraClipTM. | ||
| 520 | _aMETHODS: Standard definitions for different types of LAE were formulated and events adjudicated after detailed review by the expert panel. | ||
| 520 | _aRESULTS: Enrolling centers reported LAE in 35 cases, 11 leaflet injuries (9 tear, 2 perforation) and 24 single leaflet device attachment (SLDA). The panel confirmed LAE in 20 cases (2.0% incidence), 18 patients had SLDA and 4 had leaflet injury (2 cases had both SLDA and injury). Leaflet injury occurred during device implant and resulted in surgical valve replacement or death. SLDA-alone events were identified during implant (n=2), pre-discharge (7) or at 30 days of follow-up (7) and were resolved ( 2+ residual MR) with additional clips in 75% of cases. | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 651 | _aMedStar Heart & Vascular Institute | ||
| 657 | _aJournal Article | ||
| 700 | _aAsch, Federico M | ||
| 790 | _aAsch FM, Grayburn PA, Kar S, Little SH, Mackensen GB, Maisano F, Rinaldi MJ, Sorajja P | ||
| 856 |
_uhttps://dx.doi.org/10.4244/EIJ-D-21-00012 _zhttps://dx.doi.org/10.4244/EIJ-D-21-00012 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c6431 _d6431 |
||